Production (Stage)
Neumora Therapeutics, Inc.
NMRA
$1.02
$0.209925.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.44% | 6.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.74% | -17.91% | |||
| Operating Income | -12.74% | 17.91% | |||
| Income Before Tax | -15.42% | 18.86% | |||
| Income Tax Expenses | -- | -100.00% | |||
| Earnings from Continuing Operations | -15.60% | 18.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.60% | 18.92% | |||
| EBIT | -12.74% | 17.91% | |||
| EBITDA | -12.77% | 17.94% | |||
| EPS Basic | -15.24% | 19.62% | |||
| Normalized Basic EPS | -15.06% | 19.55% | |||
| EPS Diluted | -15.24% | 19.62% | |||
| Normalized Diluted EPS | -15.06% | 19.55% | |||
| Average Basic Shares Outstanding | 0.29% | 0.88% | |||
| Average Diluted Shares Outstanding | 0.29% | 0.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||